Literature DB >> 6134979

Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial.

S Gustavsson, H O Adami, L Lööf, A Nyberg, O Nyrén.   

Abstract

In a double-blind, dose-comparative trial, 32 patients with duodenal ulcer were assigned to receive either 20 mg/day or 60 mg/day omeprazole for 4 weeks. The 2-week healing frequency of 100% in the 60 mg/day group was significantly higher than that in the 20 mg/day group (63%). After 4 weeks all ulcers but one in the 20 mg/day group were healed (93% healing frequency). In both groups transient and mostly slight rises in serum alanine aminotransferase levels were observed (total 10 patients). One patient in the 20 mg/day group was withdrawn because of a pronounced rise in serum alanine aminotransferase on day 8. The reason for these liver reactions is not clear, but exclusion of a causal relation with omeprazole treatment must precede further clinical evaluation of this drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134979     DOI: 10.1016/s0140-6736(83)90114-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  35 in total

1.  A lyophilized aqueous extract of Maytenus ilicifolia leaves inhibits histamine-mediated acid secretion in isolated frog gastric mucosa.

Authors:  Patrícia Maria Ferreira; César Nonato de Oliveira; Alaide Braga de Oliveira; Miguel José Lopes; Fernando Alzamora; Maria Aparecida Ribeiro Vieira
Journal:  Planta       Date:  2004-03-10       Impact factor: 4.116

2.  U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

Authors:  J E Valenzuela; R G Berlin; W J Snape; T L Johnson; B I Hirschowitz; J Colon-Pagan; R S Morse; J Petrozza; G M Van Deventer; A Cagliola
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

3.  Peptic ulcer disease. Pathophysiology and current medical management.

Authors:  B F Scharschmidt
Journal:  West J Med       Date:  1987-06

4.  Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.

Authors:  F N Hussain; R A Ajjan; M Moustafa; N W Weir; S A Riley
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

5.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.

Authors:  B K Sharma; R P Walt; R E Pounder; M D Gomes; E C Wood; L H Logan
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

6.  Oral pharmacokinetics of omeprazole.

Authors:  C W Howden; P A Meredith; J A Forrest; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure.

Authors:  C W Howden; C D Payton; P A Meredith; D M Hughes; A I Macdougall; J L Reid; J A Forrest
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Omeprazole inhibits nocturnal and pentagastrin-stimulated gastric secretion in man.

Authors:  J A Wilson; E J Boyd; K G Wormsley
Journal:  Dig Dis Sci       Date:  1984-09       Impact factor: 3.199

Review 9.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

10.  Omeprazole, a gastric 'proton pump inhibitor': lack of effect on renal handling of electrolytes and urinary acidification.

Authors:  C W Howden; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.